High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1009-1014

  Kawai, Nobutoshi ^a   Yamakawa, Yuriko ^a,b   Baba, Atsuomi ^c   Nemoto, Kiyotaka ^d   Tachikawa, Hirokazu ^d   Hori, Takafumi ^d   Asada, Takashi ^d   Iidaka, Tetsuya ^e  

^a Mitsukaido Kosei Hospital   (Japan)

^b IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^c Hino Hospital   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

Author keywords

Continuous performance test; Conventional antipsychotics; Dose reduction; Wisconsin card sorting test

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERICIAZINE; SULTOPRIDE; THIORIDAZINE; TIMIPERONE; ZOTEPINE;

ACCURACY; ADULT; ANALYTICAL ERROR; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION FUNCTION; CORRELATIONAL STUDY; DATA ANALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TASK PERFORMANCE; WILCOXON SIGNED RANKS TEST; WISCONSIN CARD SORTING TEST;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33745255707     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.03.013     Document Type: Article

References (16)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. Barch D.M., Carter C.S., Braver T.S., Sabb F.W., MacDonald III A., Noll D.C., et al. Selective deficits in prefrontal cortex function in medication-naïve patients with schizophrenia. Arch Gen Psychiatry 58 (2001) 280-288
3. Cohen J.D., MacWhinney B., Flatt M., and Provost J. PsyScope: an interactive graphic system for designing and controlling experiments in the psychology laboratory using Macintosh computers. Behav Res Methods Instrum Comput 25 (1993) 257-271
4. Conley R.R., and Kelly D.L. Current status of antipsychotic treatment. Curr Drug Targets CNS Neurol Disord 1 (2002) 123-128
5. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24 (2004) 192-208
6. Goldberg T.E., Weinberger D.R., Berman K.F., Pliskin N.H., and Podd M.H. Further evidence for dementia of the prefrontal type in schizophrenia. Arch Gen Psychiatry 44 (1987) 1008-1014
7. Harvey P.D., Green M.F., Keefe R.S., and Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65 (2004) 361-372
8. Heaton R.K. The Wisconsin card sorting test manual (1981), Psychological Assessment Resources, Odessa, Fla
9. Inagaki A., Inada T., and Fujii Y. Dose equivalence of the psychotropic drugs (1999), Seiwa Shoten Publishers, Tokyo, Japan [in Japanese]
10. Kasper S., and Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28 suppl. 1 (2003) 27-38
11. Meltzer H.Y. Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9 suppl. 11 (2004) 15-24
12. Milner B. Effects of different brain lesions on card sorting: the role of the frontal lobes. Arch. Neurol 9 (1963) 90-100
13. Servan-Schreiber D., Cohen J.D., and Steingard S. Schizophrenic deficits in the processing of context. A test of a theoretical model. Arch Gen Psychiatry 53 (1996) 1105-1112
14. Sharma T., and Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26 (2003) 25-40
15. Takei N., Inagaki A., and JPSS-2 research group. Polypharmacy for psychiatric treatments in Japan. Lancet 360 (2002) 647
16. Velligan D.I., and Miller A.L. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 60 suppl. 23 (1999) 25-28